Sangamo Therapeutics, Inc (SGMOQ): Total Liabilities
$74.01M
As of 2025-12-31
$78.92M
As of 2026-03-31
-34.8%
3-year compound annual growth
-30.0%
5-year compound annual growth
+11.6%
10-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $74.01M | -6.2% | 2026-03-30, Balance as of period end |
| 2024-12-31 | $78.86M | -4.3% | 2026-03-30, Balance as of period end |
| 2023-12-31 | $82.43M | -69.2% | 2025-03-17, Balance as of period end |
| 2022-12-31 | $267.55M | -22.8% | 2024-03-13, Balance as of period end |
| 2021-12-31 | $346.58M | -21.4% | 2023-02-23, Balance as of period end |
| 2020-12-31 | $441.18M | +115.4% | 2022-02-24, Balance as of period end |
| 2019-12-31 | $204.78M | -8.2% | 2021-02-24, Balance as of period end |
| 2018-12-31 | $223.14M | +125.8% | 2020-02-28, Balance as of period end |
| 2017-12-31 | $98.84M | +355.6% | 2019-03-01, Balance as of period end |
| 2016-12-31 | $21.70M | -12.5% | 2018-03-01, Balance as of period end |
| 2015-12-31 | $24.80M | -32.2% | 2017-02-28, Balance as of period end |
| 2014-12-31 | $36.58M | +91.2% | 2016-02-18, Balance as of period end |
| 2013-12-31 | $19.13M | +8.5% | 2015-02-25, Balance as of period end |
| 2012-12-31 | $17.64M | +144.8% | 2014-02-24, Balance as of period end |
| 2011-12-31 | $7.20M | n/a | 2013-02-26, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Sangamo Therapeutics, Inc (SGMOQ) | 2025-12-31 | $74.01M | -6.2% |
| Kymera Therapeutics, Inc. (KYMR) | 2025-12-31 | $163.15M | +14.6% |
| Voyager Therapeutics, Inc. (VYGR) | 2025-12-31 | $56.20M | -39.8% |
| Editas Medicine, Inc. (EDIT) | 2025-12-31 | $159.25M | -23.2% |
| C4 Therapeutics, Inc. (CCCC) | 2025-12-31 | $102.49M | -23.3% |
| X4 Pharmaceuticals, Inc (XFOR) | 2025-12-31 | $104.17M | -16.2% |
| Fennec Pharmaceuticals Inc. (FENC) | 2025-12-31 | $35.08M | -31.0% |
| Precision Biosciences Inc (DTIL) | 2025-12-31 | $62.17M | -22.3% |
| Scilex Holding Co (SCLX) | 2025-12-31 | $576.73M | +101.9% |
Compare SGMOQ, KYMR, VYGR, EDIT side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗